BakerIDI Heart and Diabetes Institute, St Kilda Rd. Central, Melbourne, Victoria 8008, Australia.
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):313-9. doi: 10.1161/ATVBAHA.110.218669. Epub 2010 Nov 18.
High-mobility group box protein 1 (HMGB1) is a DNA-binding protein and cytokine highly expressed in atherosclerotic lesions, but its pathophysiological role in atherosclerosis is unknown. We investigated its role in the development of atherosclerosis in ApoE-/- mice.
Apolipoprotein E-deficient (ApoE-/-) mice fed a high-fat diet were administered a monoclonal anti-HMGB1 neutralizing antibody, and the effects on lesion size, immune cell accumulation, and proinflammatory mediators were assessed using Oil Red O, immunohistochemistry, and real-time polymerase chain reaction. As with human atherosclerotic lesions, lesions in ApoE-/- mice expressed HMGB1. Treatment with the neutralizing antibody attenuated atherosclerosis by 55%. Macrophage accumulation was reduced by 43%, and vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression was attenuated by 48% and 72%, respectively. CD11c+ dendritic cells were reduced by 65%, and the mature (CD83+) population was reduced by 60%. Treatment also reduced CD4+ cells by nearly 50%. mRNAs in lesions encoding tumor necrosis factor-α and interleukin-1β tended to be reduced. Mechanistically, HMGB1 stimulated macrophage migration in vitro and in vivo; in vivo, it markedly augmented the accumulation of F4/80+Gr-1(Ly-6C)+ macrophages and also increased F4/80+CD11b+ macrophage numbers.
HMGB1 exerts proatherogenic effects augmenting lesion development by stimulating macrophage migration, modulating proinflammatory mediators, and encouraging the accumulation of immune and smooth muscle cells.
高迁移率族蛋白 B1(HMGB1)是一种在动脉粥样硬化病变中高度表达的 DNA 结合蛋白和细胞因子,但它在动脉粥样硬化中的病理生理作用尚不清楚。我们研究了其在载脂蛋白 E 基因敲除(ApoE-/-)小鼠动脉粥样硬化发展中的作用。
给予高脂饮食喂养的载脂蛋白 E 基因敲除(ApoE-/-)小鼠单克隆抗 HMGB1 中和抗体,并通过油红 O、免疫组织化学和实时聚合酶链反应评估其对病变大小、免疫细胞积聚和促炎介质的影响。与人类动脉粥样硬化病变一样,ApoE-/-小鼠的病变表达 HMGB1。中和抗体治疗可使动脉粥样硬化减轻 55%。巨噬细胞积聚减少 43%,血管细胞黏附分子-1 和单核细胞趋化蛋白-1 的表达分别减少 48%和 72%。CD11c+树突状细胞减少 65%,成熟(CD83+)细胞减少 60%。治疗还使 CD4+细胞减少近 50%。病变中编码肿瘤坏死因子-α和白细胞介素-1β的 mRNAs 趋于减少。其机制是 HMGB1 刺激体外和体内巨噬细胞迁移;体内,它显著增加 F4/80+Gr-1(Ly-6C)+巨噬细胞的积聚,并增加 F4/80+CD11b+巨噬细胞的数量。
HMGB1 通过刺激巨噬细胞迁移、调节促炎介质以及促进免疫和平滑肌细胞的积聚,发挥促动脉粥样硬化作用,促进病变发展。